Express Scripts picks AbbVie over Gilead for hepatitis C drug
December 22, 2014 at 07:45 AM EST
The largest manager of U.S. prescription-drug benefits is taking AbbVie’s side in a fight between new hepatitis C treatments that cost close to $100,000 per patient.
